|
As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.
|
 |
|
National Institute for Health and Care Research (NIHR) senior programme director Joanna Calvert discusses the agency's role in achieving the 150-day metric.
|
|
|
Streeting’s resignation comes in the wake of the Labour party’s poor performance in the local elections, held on 7 May.
|
|
|
The anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose.
|
|
|
While Zatolmilast demonstrated an efficacy signal in one study in adults, the drug missed its primary endpoints across the FXS programme.
|
|
